Diflucan Price Comparison

Quick Shopping for Diflucan

1 x 50mg from IntegraRx for $59.002 x 50mg from IntegraRx for $64.003 x 50mg from IntegraRx for $69.0050 x 50mg from PharmaWebCanada for $318.171 x 100mg from IntegraRx for $64.002 x 100mg from IntegraRx for $74.003 x 100mg from IntegraRx for $84.005 x 100mg from Billing-md for $87.005 x 100mg from MPllc for $91.0010 x 100mg from Billing-md for $145.0010 x 100mg from MPllc for $159.9550 x 100mg from PharmaWebCanada for $557.851 x 150mg from PharmaWebCanada for $27.071 x 150mg from RxPayouts for $79.951 x 150mg from IntegraRx for $84.002 x 150mg from IntegraRx for $99.005 x 150mg from RxPayouts for $108.903 x 150mg from RxPayouts for $109.955 x 150mg from Billing-md for $113.003 x 150mg from IntegraRx for $119.005 x 150mg from MPllc for $123.003 x 150mg from JRB for $150.0010 x 150mg from RxPayouts for $188.1010 x 150mg from Billing-md for $199.0010 x 150mg from MPllc for $206.225 x 150mg from JRB for $250.0010 x 150mg from JRB for $350.0015 x 150mg from JRB for $450.005 x 200mg from RxPayouts for $116.105 x 200mg from MPllc for $129.9510 x 200mg from RxPayouts for $189.9010 x 200mg from MPllc for $205.00

Please see below for complete Diflucan price comparison table.

Generic Names: Fluconazole , Generic Diflucan
Brand names: Diflucan

Diflucan Price Comparison Table

Diflucan 200mg

Product	Qty	Medical Fees & Shipping	Price/ Qty	Price	Click to Order
Diflucan 200mg	5	$15.00	$23.22ea	$116.10	Buy from RxPayouts
Diflucan 200mg	5	$18.00	$25.99ea	$129.95	Buy from MPllc
Diflucan 200mg	10	$15.00	$18.99ea	$189.90	Buy from RxPayouts
Diflucan 200mg	10	$18.00	$20.50ea	$205.00	Buy from MPllc

Diflucan 150mg

Product	Qty	Medical Fees & Shipping	Price/ Qty	Price	Click to Order
Diflucan 150mg	1	$10.95	$27.07ea	$27.07	Buy from PharmaWebCanada
Diflucan 150mg	1	$15.00	$79.95ea	$79.95	Buy from RxPayouts
Diflucan 150mg	1	$18.00	$84.00ea	$84.00	Buy from IntegraRx
Diflucan 150mg	2	$18.00	$49.50ea	$99.00	Buy from IntegraRx
Diflucan 150mg	3	$15.00	$36.65ea	$109.95	Buy from RxPayouts
Diflucan 150mg	3	$18.00	$39.67ea	$119.00	Buy from IntegraRx
Diflucan 150mg	3	$18.00	$50.00ea	$150.00	Buy from JRB
Diflucan 150mg	5	$15.00	$21.78ea	$108.90	Buy from RxPayouts
Diflucan 150mg	5	$18.00	$22.60ea	$113.00	Buy from Billing-md
Diflucan 150mg	5	$18.00	$24.60ea	$123.00	Buy from MPllc
Diflucan 150mg	5	$18.00	$50.00ea	$250.00	Buy from JRB
Diflucan 150mg	10	$15.00	$18.81ea	$188.10	Buy from RxPayouts
Diflucan 150mg	10	$18.00	$19.90ea	$199.00	Buy from Billing-md
Diflucan 150mg	10	$18.00	$20.62ea	$206.22	Buy from MPllc
Diflucan 150mg	10	$18.00	$35.00ea	$350.00	Buy from JRB
Diflucan 150mg	15	$18.00	$30.00ea	$450.00	Buy from JRB

Diflucan 100mg

Product	Qty	Medical Fees & Shipping	Price/ Qty	Price	Click to Order
Diflucan 100mg	1	$18.00	$64.00ea	$64.00	Buy from IntegraRx
Diflucan 100mg	2	$18.00	$37.00ea	$74.00	Buy from IntegraRx
Diflucan 100mg	3	$18.00	$28.00ea	$84.00	Buy from IntegraRx
Diflucan 100mg	5	$18.00	$17.40ea	$87.00	Buy from Billing-md
Diflucan 100mg	5	$18.00	$18.20ea	$91.00	Buy from MPllc
Diflucan 100mg	10	$18.00	$14.50ea	$145.00	Buy from Billing-md
Diflucan 100mg	10	$18.00	$15.99ea	$159.95	Buy from MPllc
Diflucan 100mg	50	$10.95	$11.16ea	$557.85	Buy from PharmaWebCanada

Diflucan 50mg

Product	Qty	Medical Fees & Shipping	Price/ Qty	Price	Click to Order
Diflucan 50mg	1	$18.00	$59.00ea	$59.00	Buy from IntegraRx
Diflucan 50mg	2	$18.00	$32.00ea	$64.00	Buy from IntegraRx
Diflucan 50mg	3	$18.00	$23.00ea	$69.00	Buy from IntegraRx
Diflucan 50mg	50	$10.95	$6.36ea	$318.17	Buy from PharmaWebCanada

When buying online you have to be aware of a few things:

• All our pharmacies offer free consultation by licensed Doctors, were required.
• Some Pharmacies offer next Day Shipping or Saturday Shipping. This may cost extra.
• All shipping costs are shown before you place your order
• Private & Confidential Service, Secure Online Order Form.

Diflucan Information

Brand Name: Diflucan

Diflucan is a tablet you swallow to treat vaginal yeast infections caused by a yeast called Candida. It helps stop too much yeast from growing in the vagina so the yeast infection goes away.

Diflucan is different from other treatments for vaginal yeast infections because it is a tablet taken by mouth.

Diflucan Indications

Diflucan (fluconazole) is indicated for the treatment of:

1. Vaginal Candidiasis (vaginal yeast infections due to Candida).
2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia.
3. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted.

Prophylaxis

Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone wmarrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.

Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

Diflucan Ingredients and Composition

Diflucan (fluconazole), the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, as a powder for oral suspension and as a sterile solution for intravenous use in glass and in Viaflex Plus plastic containers.

Diflucan (fluconazole) is designated chemically as 2,4-difluoro-a,a1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C₁₃H₁₂F₂N₆O and molecular weight 306.3.

Diflucan (fluconazole) is a white crystalline solid which is slightly soluble in water and saline.

Diflucan Tablets: Contain 50, 100, or 200 mg of fluconazole and the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, povidone, croscarmellose sodium, FD&C red no. 40 aluminum lake dye, and magnesium stearate.

Diflucan for Oral Suspension: Contains 350 mg or 1400 mg of fluconazole and the following inactive ingredients: sucrose, sodium citrate dihydrate, citric acid anhydrous, sodium benzoate, titanium dioxide, colloidal silicon dioxide, xanthan gum and natural orange flavor. After reconstitution with 24 ml of distilled water or Purified Water (USP), each ml of reconstituted suspension contains 10 mg or 40 mg of fluconazole.

Diflucan Injection: It is an iso-osmotic, sterile, nonpyrogenic solution of fluconazole in a sodium chloride or dextrose diluent. Each ml contains 2 mg of fluconazole and 9 mg of sodium chloride or 56 mg of dextrose, hydrous. The pH ranges from 4.0 to 8.0 in the sodium chloride diluent and from 3.5 to 6.5 in the dextrose diluent. Injection volumes of 100 ml and 200 ml are packaged in glass and in Viaflex Plus plastic containers.

The Viaflex Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic) (Viaflex and PL 146 are registered trademarks of Baxter International, Inc.). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexylphthalate (DEHP), up to 5 parts per million. However, the suitability of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

How Does Diflucan Work?

Mode of Action

Fluconazole, the active ingredient in Diflucan, is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 alpha-demethylation. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. The subsequent loss of normal sterols correlates with the accumulation of 14 alpha-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole.

How To Take Diflucan and Diflucan Dosage and Administration

Single Dose

Vaginal candidiasis: The recommended Diflucan dosage of for vaginal candidiasis is 150 mg as a single oral dose.

Multiple Dose

SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF DIFLUCAN IS THE SAME FOR ORAL (TABLETS AND SUSPENSION) AND INTRAVENOUS ADMINISTRATION. In general, a leading dose of twice the daily dose is recommended on the first day of therapy to result in plasma concentrations close to steady-state by the second day of therapy.

The daily dose of Diflucan for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient's response to therapy. Treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.

Oropharyngeal Candidiasis

The recommended Diflucan dosage for oropharyngeal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Clinical evidence of oropharyngeal candidiasis generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse.

Esophageal Candidiasis

The recommended Diflucan dosage for esophageal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Doses up to 400 mg/day may be used, based on medical judgment of the patient's response to therapy. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.

Systemic Candida Infections: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia, optimal therapeutic dosage and duration of therapy have not been established. In open, noncomparative studies of small numbers of patients, doses of up to 400 mg daily have been used.

Urinary Tract Infection and Peritonitis: For the treatment of Candida urinary tract infections and peritonitis, daily doses of 50-200 mg have been used in open, noncomparative studies of small numbers of patients.

Cryptococcal Meningitis

The recommended Diflucan dosage for treatment of acute cryptococcal meningitis is 400 mg on the first day, followed by 200 mg once daily. A dosage of 400 mg once daily may be used, based on medical judgment of the patient's response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10-12 weeks after the cerebrospinal fluid becomes culture negative. The recommended dosage of fluconazole for suppression of relapse of cryptococcal meningitis in patients with AIDS is 200 mg once daily.

Prophylaxis in Patients Undergoing Bone Marrow Transplantation: The recommended Diflucan daily dosage for the prevention of candidiasis of patients undergoing bone wmarrow transplantation is 400 mg once daily. Patients who are anticipated to have severe granulocytopenia (less than 500 neutrophils per cu mm) should start fluconazole prophylaxis several days before the anticipated onset of neutropenia, and continue for 7 days after the neutrophil count rises above 1000 cells per cu mm.

If you suspect a Diflucan Overdose

There has been one reported case of overdosage with Diflucan (fluconazole). A 42-year-old patient infected with human immunodeficiency virus developed hallucinations and exhibited paranoid behavior after reportedly ingesting 8200 mg of fluconazole. The patient was admitted to the hospital, and his condition resolved within 48 hours.

In the event of Diflucan overdose, symptomatic treatment (with supportive measures and gastric lavage if clinically indicated) should be instituted.

Fluconazole is largely excreted in urine. A three hour hemodialysis session decreases plasma levels by approximately 50%.

In mice and rats receiving very high doses of fluconazole, clinical effects in both species included decreased motility and respiration, ptosis, lacrimation, salivation, urinary incontinence, loss of righting reflex and cyanosis; death was sometimes preceded by clonic convulsions.

Diflucan Side Effects

In Patients Receiving a Single Diflucan Dose for Vaginal Candidiasis: During comparative clinical studies conducted in the United States, 448 patients with vaginal candidiasis were treated with Diflucan, 150 mg single dose. The overall incidence of side effects possibly related to Diflucan was 26%. In 422 patients receiving active comparative agents, the incidence was 16%. The most common treatment-related adverse events reported in the patients who received 150 mg single dose fluconazole for vaginitis were headache (13%), nausea (7%), and abdominal pain (6%). Other side effects reported with an incidence equal to or greater than 1% included diarrhea (3%), dyspepsia (1%), dizziness (1%), and taste perversion (1%). Most of the reported side effects were mild to moderate in severity. Rarely, angioedema and anaphylactic reaction have been reported in marketing experience.

In Patients Receiving Multiple Diflucan Doses for Other Infections: Sixteen percent of over 4000 patients treated with fluconazole in clinical trials of 7 days or more experienced adverse events. Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of patients due to laboratory test abnormalities.

Clinical Diflucan side effects were reported more frequently in HIV infected patients (21%) than in non-HIV infected patients (13%); however, the patterns in HIV infected and non-HIV infected patients were similar. The proportions of patients discontinuing therapy due to clinical adverse events were similar in the two groups (1.5%).

The following treatment-related clinical Diflucan side effects occurred at an incidence of 1% or greater in 4048 patients receiving Diflucan for 7 or more days in clinical trials:

• nausea 3.7%
• headache 1.9%
• skin rash 1.8%
• vomiting 1.7%
• abdominal pain 1.7%
• and diarrhea 1.5%

The following adverse events have occurred under conditions where a casual association is probable:

Hepatobiliary

In combined clinical trials and marketing experience, there have been rare cases of serious hepatic reactions during treatment with fluconazole. The spectrum of these hepatic reactions has ranged from mild transient elevations in transaminases to clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities. Instances of fatal hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly AIDS or malignancy) and often while taking multiple concomitant medications. Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. In each of these cases, liver function returned to baseline on discontinuation of fluconazole.

In two comparative trials evaluating the efficacy of Diflucan for the suppression of relapse of cryptococcal meningitis, a statistically significant increase was observed in median AST (SGOT) levels from a baseline value of 30 IU/l to 41 IU/l in one trial and 34 IU/l to 66 IU/l in the other. The overall rate of serum transaminase elevations of more than 8 times the upper limit of normal was approximately 1% in fluconazole-treated patients in clinical trials. These elevations occurred in patients with severe underlying disease, predominantly AIDS or malignancies, most of whom were receiving multiple concomitant medications, including many known to be hepatotoxic. The incidence of abnormally elevated serum transaminases was greater in patients taking fluconazole concomitantly with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea hypoglycemic agents.

Immunological

In rare cases, anaphylaxis has been reported.

The following adverse events have occurred under conditions where a casual association is uncertain:

Central Nervous System

• Seizures

Dermatologic

Exfoliative skin disorders including Stevens-Johnson Syndrome and toxic epidermal necroivsis (See WARNINGS, alopecia).

Hematopoietic and Lymphatic

• Leukopenia
• thrombocytopenia

Metabolic

• Hypercholesterolemia
• hypertriglyceridemia
• hypokalemia.

Adverse Reactions in Children: In phase 2/3 clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with fluconazole at doses up to 15 mg/kg/day for up to 1,616 days. Thirteen percent of children experienced treatment related adverse events. The most commonly reported events were vomiting (5%), abdominal pain (3%), nausea (2%), and diarrhea (2%). Treatment was discontinued inn 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase.

Percentage of Patients with Treatment-Related Diflucan Side Effects

As with any medication, you may experience additional Diflucan side effects.

Diflucan Warnings

1. Hepatic injury: Diflucan (fluconazole) has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of the patient has been observed. Fluconazole hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury. Diflucan (fluconazole) should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole.
2. Anaphylaxis: In rare cases, anaphylaxis has been reported.
3. Dermatologic: Patients have rarely developed exfoliative skin disorders during treatment with Diflucan (fluconazole). In patients with serious underlying diseases (predominantly AIDS and malignancy), these have rarely resulted in a fatal outcome. Patients who develop rashes during treatment with fluconazole should be monitored closely and the drug discontinued if lesions progress.

Diflucan Precautions and Contraindications

General

Single Dose: The convenience and efficacy of the single dose oral tablet of Diflucan (fluconazole) regimen for the treatment of vaginal yeast infections should be weighed against the acceptability of a higher incidence of drug related adverse events with fluconazole (26%) versus intravaginal agents (16%) in U.S. comparative clinical studies.

Contraindications to Diflucan

Diflucan (fluconazole) is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles.

Diflucan Pill Identification / ID and Appearance

Diflucan Tablets: Pink trapezoidal tablets containing 50, 100 or 200 mg of fluconazole are packaged in bottles or unit dose blisters. The 150 mg fluconazole tablets are pink and oval shaped, packaged in a single dose unit blister.

Storage: Store tablets below 86°F (30°C).

Diflucan for Oral Suspension: Diflucan for oral suspension is supplied as an orange-flavored powder to provide 35 ml per bottle.

Storage: Store dry powder below 86°F (30°C). Store reconstituted suspension between 86°F (30°C) and 41°F (5°C) and discard unused portion after 2 weeks. Protect from freezing.

Diflucan Injections: Diflucan injections for intravenous infusion administration are formulated as sterile iso-osmotic solutions containing 2 mg/ml of fluconazole. They are supplied in glass bottles or in Viaflex Plus plastic containers containing volumes of 100 ml or 200 ml affording doses of 200 mg and 400 mg of fluconazole, respectively.

Storing Diflucan

Storage: Store between 86°F (30°C) and 41°F (5°C). Protect from freezing.Diflucan injections in Viaflex Plus plastic containers are available in both sodium chloride and dextrose diluents. Storage: Store between 77°F (25°C) and 41°F (5°C). Brief exposure up to 104°F (40°C) does not adversely affect the product. Protect from freezing.

Credits for Diflucan Information

Diflucan information on this page is copyright by Drug Information at Pharma-Help.com, reprinted with Permission. All Rights Reserved. Other pages with reprint permission include Diflucan.

Daily updates, current date: 5th of July 2009